Cancer name Ovarian Cancer
Cancer Type OV
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment mbIL-12
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature CD36
Official Symbol CD36
Mode of action TRAN_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Several signals involved in inflammatory recruitment and proliferation (Ccl5,Cd36,Gmcsf,Tnfa) were also significantly reduced (P<0.01) in MOSE-LFFLv, compared with PBS control animals.
PMID 26430781
Title Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer.